Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update assessing safety and efficacy of the fixed-dose combination emtricitabine/tenofovir alafenamide (F/TAF) for HIV-1 pre-exposure pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/tenofovir alafenamide (F/TAF) (emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: Pre-Exposure Prophylaxis of HIV-1 Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-03-17